THE BLOG
let’s talk about biomarkers – CD19
B-lymphocyte antigen CD19 or CD19 [Cluster of Differentiation 19] is a protein that is encoding by the CD19 gene and is expressed in B-cells [B-cells are a type of white blood cell]. because CD19 is expressed on all B-cells [80% of ALL, 88% of B-cell lymphomas and...
let’s talk about biomarkers- BRCA
BRCA1 [BReast CAncer gene 1] and BRCA2 [BReast CAncer gene 2] are genes that produce proteins that help repair damaged DNA. everyone has two copies of each of these genes—inherited from each parent and despite what their names suggest, BRCA1 and BRCA2 do not cause...
tumour agnostic therapies are redefining cancer care
with an increased focus on precision medicine, a revolutionary new approach to cancer treatment, patient care and drug development has emerged - tumour agnostic therapies. tumour agnostic therapy is a type of therapy that uses drugs or other substances to treat cancer...
current biomarkers in cancer
biomarker testing has revolutionized cancer treatment for many tumour types. biomarkers is a term used to describe many different potential markers of cancer development and progression. these markers can come in many forms - proteins, biochemicals, DNA and...
understanding targeted therapies
different therapies exist to treat cancer - systemic therapies, like chemotherapy, attack both normal and cancerous cells, while targeted therapies inhibit or solicit molecular pathways - acting on specific molecular targets that are associated with the cancer. ...
understanding biomarkers
because we know that cancer can be highly variable from one person to the other, based on the changes at the molecular level, each patient, even those with the same diagnosis, have a unique set of changes that influence how a person will respond to therapy, or how...
fittingly on this last day of november and #precisionmedicine awareness month we’re tuned in to @GenomeCanada town hall on the future of genomics in canada